Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.79 Million USD | 2.83% |
| 2022 | 1.74 Million USD | 0.23% |
| 2021 | 1.74 Million USD | -4.97% |
| 2020 | 1.83 Million USD | -27.18% |
| 2019 | 2.52 Million USD | 115.92% |
| 2018 | 1.16 Million USD | 29.94% |
| 2017 | 898.52 Thousand USD | -33.12% |
| 2016 | 1.34 Million USD | 28.27% |
| 2015 | 1.04 Million USD | 31.53% |
| 2014 | 796.27 Thousand USD | -19.8% |
| 2013 | 992.84 Thousand USD | -20.98% |
| 2012 | 1.25 Million USD | -86.7% |
| 2011 | 9.44 Million USD | 160.44% |
| 2010 | 3.62 Million USD | 543.98% |
| 2009 | 563.2 Thousand USD | -68.2% |
| 2008 | 1.77 Million USD | 434.36% |
| 2007 | 331.49 Thousand USD | 1.2% |
| 2006 | 327.57 Thousand USD | -12.61% |
| 2005 | 374.83 Thousand USD | -12.75% |
| 2004 | 429.62 Thousand USD | 103.74% |
| 2003 | 210.86 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 908.68 Thousand USD | -49.47% |
| 2024 Q2 | 1.38 Million USD | 52.23% |
| 2023 Q4 | 1.79 Million USD | 28.25% |
| 2023 FY | 1.79 Million USD | 2.83% |
| 2023 Q1 | 1.88 Million USD | 7.8% |
| 2023 Q2 | 1.2 Million USD | -35.97% |
| 2023 Q3 | 1.4 Million USD | 16.16% |
| 2022 Q1 | 1.66 Million USD | -4.7% |
| 2022 Q3 | 1.7 Million USD | 1.48% |
| 2022 FY | 1.74 Million USD | 0.23% |
| 2022 Q4 | 1.74 Million USD | 2.71% |
| 2022 Q2 | 1.67 Million USD | 0.91% |
| 2021 Q4 | 1.74 Million USD | -31.44% |
| 2021 FY | 1.74 Million USD | -4.97% |
| 2021 Q3 | 2.54 Million USD | 1.22% |
| 2021 Q2 | 2.51 Million USD | 91.14% |
| 2021 Q1 | 1.31 Million USD | -28.36% |
| 2020 Q4 | 1.83 Million USD | 11.82% |
| 2020 FY | 1.83 Million USD | -27.18% |
| 2020 Q3 | 1.64 Million USD | -15.54% |
| 2020 Q2 | 1.94 Million USD | -26.73% |
| 2020 Q1 | 2.65 Million USD | 5.24% |
| 2019 FY | 2.52 Million USD | 115.92% |
| 2019 Q1 | 2.18 Million USD | 87.15% |
| 2019 Q2 | 2.51 Million USD | 14.87% |
| 2019 Q3 | 2.83 Million USD | 12.88% |
| 2019 Q4 | 2.52 Million USD | -11.02% |
| 2018 Q4 | 1.16 Million USD | -25.01% |
| 2018 Q2 | 1.55 Million USD | 32.13% |
| 2018 Q1 | 1.17 Million USD | 31.24% |
| 2018 FY | 1.16 Million USD | 29.94% |
| 2018 Q3 | 1.55 Million USD | -0.07% |
| 2017 Q2 | 4.07 Million USD | 249.43% |
| 2017 FY | 898.52 Thousand USD | -33.12% |
| 2017 Q4 | 898.52 Thousand USD | -78.2% |
| 2017 Q3 | 4.12 Million USD | 1.24% |
| 2017 Q1 | 1.16 Million USD | -13.26% |
| 2016 Q4 | 1.34 Million USD | 47.75% |
| 2016 FY | 1.34 Million USD | 28.27% |
| 2016 Q1 | 1.08 Million USD | 3.43% |
| 2016 Q2 | 897.79 Thousand USD | -17.12% |
| 2016 Q3 | 909.28 Thousand USD | 1.28% |
| 2015 Q2 | 5.6 Million USD | 824.33% |
| 2015 FY | 1.04 Million USD | 31.53% |
| 2015 Q4 | 1.04 Million USD | -82.21% |
| 2015 Q3 | 5.88 Million USD | 5.09% |
| 2015 Q1 | 605.98 Thousand USD | -23.9% |
| 2014 Q1 | 938.1 Thousand USD | -5.51% |
| 2014 Q2 | 777.86 Thousand USD | -17.08% |
| 2014 FY | 796.27 Thousand USD | -19.8% |
| 2014 Q4 | 796.27 Thousand USD | 7.68% |
| 2014 Q3 | 739.5 Thousand USD | -4.93% |
| 2013 FY | 992.84 Thousand USD | -20.98% |
| 2013 Q4 | 992.84 Thousand USD | -77.7% |
| 2013 Q3 | 4.45 Million USD | 220.83% |
| 2013 Q1 | 1.17 Million USD | -6.6% |
| 2013 Q2 | 1.38 Million USD | 18.26% |
| 2012 Q4 | 1.25 Million USD | -28.32% |
| 2012 Q2 | 3.43 Million USD | 52.14% |
| 2012 Q1 | 2.25 Million USD | -76.12% |
| 2012 FY | 1.25 Million USD | -86.7% |
| 2012 Q3 | 1.75 Million USD | -48.92% |
| 2011 Q2 | 6.29 Million USD | 39.29% |
| 2011 FY | 9.44 Million USD | 160.44% |
| 2011 Q1 | 4.51 Million USD | 24.55% |
| 2011 Q3 | 7.8 Million USD | 24.11% |
| 2011 Q4 | 9.44 Million USD | 20.96% |
| 2010 Q1 | 641.51 Thousand USD | 13.9% |
| 2010 FY | 3.62 Million USD | 543.98% |
| 2010 Q4 | 3.62 Million USD | 47.14% |
| 2010 Q3 | 2.46 Million USD | 40.09% |
| 2010 Q2 | 1.75 Million USD | 174.29% |
| 2009 Q4 | 563.2 Thousand USD | -71.45% |
| 2009 FY | 563.2 Thousand USD | -68.2% |
| 2009 Q1 | 2.63 Million USD | 48.92% |
| 2009 Q2 | 3.41 Million USD | 29.44% |
| 2009 Q3 | 1.97 Million USD | -42.22% |
| 2008 Q2 | 365.36 Thousand USD | -8.22% |
| 2008 FY | 1.77 Million USD | 434.36% |
| 2008 Q4 | 1.77 Million USD | 274.07% |
| 2008 Q3 | 473.54 Thousand USD | 29.61% |
| 2008 Q1 | 398.09 Thousand USD | 20.09% |
| 2007 Q4 | 331.49 Thousand USD | 33.88% |
| 2007 FY | 331.49 Thousand USD | 1.2% |
| 2007 Q2 | 374.69 Thousand USD | 3.38% |
| 2007 Q1 | 362.43 Thousand USD | 10.64% |
| 2007 Q3 | 247.6 Thousand USD | -33.92% |
| 2006 Q2 | 399.77 Thousand USD | 8.53% |
| 2006 Q1 | 368.35 Thousand USD | -1.73% |
| 2006 FY | 327.57 Thousand USD | -12.61% |
| 2006 Q4 | 327.57 Thousand USD | 0.69% |
| 2006 Q3 | 325.32 Thousand USD | -18.62% |
| 2005 Q3 | 764.61 Thousand USD | -5.85% |
| 2005 Q4 | 374.83 Thousand USD | -50.98% |
| 2005 Q2 | 812.14 Thousand USD | -2.61% |
| 2005 FY | 374.83 Thousand USD | -12.75% |
| 2005 Q1 | 833.9 Thousand USD | 94.1% |
| 2004 Q3 | 326.81 Thousand USD | 54.4% |
| 2004 FY | 429.62 Thousand USD | 103.74% |
| 2004 Q1 | 209.78 Thousand USD | -0.52% |
| 2004 Q2 | 211.67 Thousand USD | 0.9% |
| 2004 Q4 | 429.62 Thousand USD | 31.46% |
| 2003 Q4 | 210.86 Thousand USD | -10.81% |
| 2003 Q2 | 334.44 Thousand USD | 0.0% |
| 2003 FY | 210.86 Thousand USD | 0.0% |
| 2003 Q3 | 236.43 Thousand USD | -29.31% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | 80.341% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | 24.319% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 98.734% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 96.01% |
| Azitra, Inc. | 2.2 Million USD | 18.351% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | 51.997% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | 72.509% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 90.149% |
| CEL-SCI Corporation | 17.31 Million USD | 89.614% |
| iBio, Inc. | 7.41 Million USD | 75.733% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 95.389% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | 74.635% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 96.119% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 85.632% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | 68.563% |
| NanoViricides, Inc. | 1.35 Million USD | -32.338% |
| BiomX Inc. | 55.07 Million USD | 96.735% |
| BiomX Inc. | 55.07 Million USD | 96.735% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 96.465% |
| Palatin Technologies, Inc. | 10.85 Million USD | 83.433% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 92.094% |